To assess the prognostic value of coronary CT angiography (CTA) for prediction of major adverse cardiac events (MACE) over a long-term follow-up period.
Introduction
Coronary artery disease (CAD) causes a high socioeconomic burden; thus, identifying patients at risk for major adverse cardiac events (MACE) at the earliest time point is desirable.
Non-invasive screening with coronary computed tomography angiography (CTA) is a valuable tool 1,2 for early diagnosis of CAD. The strength of CTA encompasses a high sensitivity and negative predictive value of 90 -99% 3 for coronary stenosis detection .50% along with the advantage of coronary plaque characterization and plaque burden estimation as valuable prognostic parameters. 4, 5 Currently, emerging research is focusing on improving coronary risk stratification tools by using CTA parameters, 6, 7 which recently showed a higher accuracy (c ¼ 0.76) than the Diamond -Forrester score (c ¼ 0.64). 7 High-risk plaque (HRP) criteria by CTA are specific indicators for 'vulnerable plaque', which may allow an early identification of patients at risk for future MACE. 8 -15 Thus, they could further sharpen risk calculators. However, little prospective outcome data are available to date for enrolling small sample sizes or collecting short-or mid-term outcomes. 14 -16 Besides, a variety of different HRP criteria have been proposed: the napkin-ring (NR) sign, 8 a pathohistological correlate for advanced/vulnerable atherosclerotic lesions, positive remodelling and spotty calcification (SC), 9, 11 and low-attenuation plaque (LAP) with ,30 Hounsfield units (HU) measured by plaque 'area ROI' (region of interest) 9 or by 'pixel lens' screening techniques. 10 In contrast, ex vivo studies identified LAP ,60 12 and ,90 HU 13 as optimal cut-offs for lipid-core plaque. However, another study could not correlate the NR sign with thin-cap fibroatheroma (TCFA), a macrophage infiltration. 10 Therefore, the purpose of our study was to determine the prognostic value of coronary CTA parameters focusing on the various proposed HRP criteria for prediction of MACE over a long-term period.
Methods Study design and population
This prospective cohort study was approved by our local institutional review board. Consecutive patients referred to coronary CTA 2 Exclusion criteria were known CAD, previous percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), previous MI or heart valve surgery, heart valve disease, renal dysfunction (estimated GFR ,60 mL/min/1.73 m 2 ), pregnancy, age ,21 years, atrial fibrillation for 64-slice CT, and patients with positive troponin, unstable angina, and acute chest pain prior to CTA.
Computed tomography angiography
Non-contrast ECG-gated coronary calcium score (CCS) computed tomography (CT) with standardized scan parameters (detector collimation 64 × 1.5 mm; 120 kV) was performed, and the Agatston score was calculated. Then, coronary CTA was appended using either a 64-slice CTA (Sensation 64, Siemens) (until December 2009) or 128-slice dualsource CTA (Definition FLASH, Siemens) (until June 2011) with a detector collimation of 2 × 64 × 0.6 mm and a z-flying spot or 64 × 0.6 mm and a rotation time of 0.28 or 0.33 s, respectively. In patients examined with 64-slice CT, retrospective ECG gating was applied. In patients undergoing 128-slice dual-source CT, prospective ECG triggering was used in regular heart rates of ,65 bpm (diastolic padding, 70% of RR interval) and .65 bpm (systolic padding, 40% RR interval) (padding window + 5%), and retrospective ECG gating was used in patients with arrhythmia.
An iodine contrast agent (Iopromide, Ultravist 370) was injected intravenously (flow rate of 4 -6 mL/s + 40 cc saline chaser), triggered 
CTA image analysis
Curved multiplanar reformations (cMPR) and oblique interactive MPR using 3D post-processing software (SyngoVia, Siemens) were generated:
(1) Coronary stenosis severity was scored by visual estimation as minimal ,10%, mild ≤49%, intermediate 50-69%, or severe ≥70% per coronary segment (AHA-modified-17-segment classification).
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(2) Plaque types were characterized as calcified, 1 mixed (dominantly calcified), 2 mixed (dominantly non-calcified), 3 and non-calcified 4 per coronary segment. 20 Calcified and non-calcified plaques were defined as hyper-and hypo-attenuating lesions, 21 respectively.
The coronary segment involvement score was calculated. (3) Quantitative HRP analysis in lesions with non-calcified plaque component 2 -4 was performed: † LAP: CT density was screened with the 'pixel lens', and the minimal HU was recorded. 10 Then, an area ROI 9 was placed into the lowest density plaque area and drawn as large as possible, while sparing areas affected by artefacts or adjacent to calcifications. LAP was defined as a hypo-attenuating lesion with ,130 HU. 20 If a patient had multiple lesions, the one with the lowest HU was selected. † NR sign was defined 8, 22, 23 as an outer high-density rim (,200 HU) with an inner hypodense area (,130 HU), which was (i) not adjacent to a calcification (to avoid beam hardening artefact) and (ii) present on a minimum of two adjacent axial 1 mm slices. † SC was defined as calcification ,3 mm size. † The RI was calculated as the ratio of the maximal cross-sectional vessel diameter, including the plaque and the lumen, and its closest proximal (or distal, in ostial lesions) normal reference vessel lumen diameter.
Image analysis was performed by two independent observers (.6-month and 10-year experience). Consensus reading was obtained. Plaques with image quality limitations such as artefacts (motion blurring, high image noise, beam hardening, or streak artefacts) were excluded from quantitative HRP analysis.
Outcome and follow-up data collection 
Statistical analysis
Statistical analysis was performed using SPSS software (V17.0, SPSS Inc., Chicago, IL, USA) and MedCalc (V12.5, Belgium). Quantitative variables are expressed as means + standard deviation (SD), and categorical variables are expressed as absolute values and percentages. A P-value of ,0.05 was considered as significant.
Mean differences between parametric data were tested with the independent t-test and with x 2 or Fisher's exact test for categorical data.
Univariate and multivariable proportional hazards risk models were created for prediction of MACE. The multivariate models were adjusted for conventional coronary risk factors (age, gender, arterial hypertension, nicotine, positive family history, BMI, dyslipidaemia, diabetes) and the CTA findings (stenosis severity and plaque type).
Multivariate linear regression analysis was performed to assess dependencies among conventional risk factors and the CTA findings [stenosis severity, plaque type, calcium score, and HRP features (LAP ,30, ,60, and ,90 HU, NR, SC, RI)] and receiver-operating curve (ROC) analysis to identify LAP-HU and RI thresholds for MACE prediction.
Results
Of 7242 patients screened, 1469 were finally included ( Figure 1 and Table 1 ). Follow-up (F/U)-interval was 2851 + 540 days (mean, 7.8 years; range, 4.8 -9.8).
Primary endpoint
There were 41 (2.8%) MACE (21 STEMI, 15 NSTEMI, 3 MI diagnosed post-mortem by pathohistology and 2 unstable AP). Cardiac mortality was n ¼ 7 (0.5%). Time from CTA to MACE was mean 1150.7 days (3.1 years) (range, 0 -3368 days). Maximal Hs-troponin during MACE was mean 2909.8 mg/dL. No (0%) MACE occurred in patients with negative CTA (¼absence of plaques and stenosis). Six MACE occurred in patients with calcium score zero but noncalcified plaque by CTA.
Secondary endpoint
Coronary revascularization rate was 146 (9.9%) (37 CABG, 109 PCI). ICA rate was 340/1469 (23.1%). There were three MACE after a PCI following a CTA with .50% stenosis [n ¼ 1: new culprit lesion circumflex artery (CX) ( Figure 2) ; n ¼ 1: in-stent restenosis (excluded from HRP analysis); n ¼ 1: right coronary artery stent patent, left coronary artery non-significant ,50% culprit lesion causing NSTEMI-ACS].
CTA stenosis severity and plaque types MACE rate significantly (P , 0.001) (Figure 3 ) increased along with stenosis severity by CTA ( Table 2 ) and with increasing non-calcified plaque component (Table 3 and Figure 4) , and a higher MACE rate for mixed dominantly non-calcified and non-calcified when compared with that for exclusively or dominantly calcified plaque was noted (P , 0.001) ( Table 4) .
Quantitative HRP analysis
A total of 89 (7.5%) of the 673 plaques were excluded from analysis due to image quality limitations, the majority (80/89, 90%) in patients undergoing 64-slice CT. Finally, 584 plaques (n ¼ 68 in MACE) were evaluated. Among the n ¼ 516 in non-MACE, 33 lesions were excluded from LAP-HU quantification only due to high image noise (.35SD of HU). Interobserver agreement was kappa (k) ¼ 0.79. LAP density was lower in patients with MACE (Table 5) , and the prevalence of LAP ,30, ,60, and ,90 HU was higher (P , 0.001). NR sign was more often found in patients who experienced MACE with n ¼ 26 (63.4%) vs. n ¼ 40 (2.8%) (P , 0.001) ( Table 6 ). In MACE-free patients, the cumulative numbers of LAP with increasing CT density from ,30 to ,90 HU increased from n ¼ 34 to n ¼ 100. SCs were more frequently found in MACE, while their absolute count (n ¼ 206) was high in MACE-free patients. The RI was higher in the MACE group, and AUC was c ¼ 0.68 (P ¼ 0.001) with RI ¼ 1.28 (sensitivity 78.4%, specificity 54%) as the best cut-off. For plaque density, AUC was c ¼ 0.895 (P , 0.0001), and 63 HU (sensitivity 89.2%, specificity 82.3%) was identified as the optimal threshold. Kaplan -Meier curves showed adverse prognosis in patients in whom the NR sign and LAP ,60 HU were present ( Figures 5) .
Both univariable and unadjusted multivariable Cox proportional hazard models (Tables 7 and 8) revealed LAP ,60 HU and NR sign as the strongest MACE predictors, while SC, stenosis severity, and plaque type were less powerful. After adjusting for conventional risk factors, CT-stenosis severity and plaque type, LAP ,60 HU, and NR remained predictive, while the effect of NR sign was even enhancing. SC was a weaker predictor, while RI was non-significant. Prevalence of SC in mixed dominantly calcifying plaques was low with 37/207 (17.8%).
On multivariate regression analysis, the HRP criteria were independent from CTA stenosis severity, plaque type, and other conventional risk factors (arterial hypertension, nicotine, positive family history, dyslipidaemia, diabetes, BMI ,25 kg/m 2 , age, and gender). The HRP features among each other were dependent.
Discussion
First, our prospective study identified the HRP criteria LAP ≤60 HU and the NR sign as the most powerful parameters for the prediction of MACE in patients with low-to-intermediate CAD risk during a long-term follow-up period. Other applied thresholds (LAP ,30 and ,90 HU) were less, but still highly predictive, with a higher strength than SC and stenosis severity by CTA. Our findings are in line with an ex vivo study 12 showing LAP ,60 HU by ROI-plaque area tracing as a valuable marker for lipidcore plaque detection. 12 Lipid-rich tissue is characterized by lower CT attenuation than fibrous, and a cut-off of at least 5.5% of pixels with an attenuation of ≤30 HU allowed for the accurate identification of lipid-rich plaques (sensitivity 95%, specificity 80%) compared with intravascular ultrasound histogram analysis. 25 Consistently, our data also revealed the LAP ,30 HU cut-off as a strong prognostic marker for MACE, for both the 'area ROI' LAP technique 9 and the HU 'pixel lens' screening. 10 In this comparative study with OCT, 10 LAP ,30 HU was associated with TCFA and macrophage infiltration (OR 11.2, P , 0.001). 10 A single pixel with low HU may also reflect an artefact, thus making the 'pixel lens' technique more susceptible for artefacts, but more sensitive for intraplaque submillimetre lipid accumulations. Currently, in vivo prospective outcome data on the value of HRP criteria are rare. 11,14 -16 In 260 patients 11 with acute chest pain (ROMICAT-II), a dedicated risk score including LAP ,60 HU, RI, SC, lesion length, and other CTA parameters showed accurate forecasting of ACS, and other ROMICAT data 16 showed in 472 patients independent prediction of ACS by HRP (OR 8.9; P ¼ 0.006) using LAP ,30 HU as cut-off, after adjustment for ≥50% stenosis and clinical risk factors. In 895 patients 14 during short-term (2.3 years) F/U, positive remodelling (P , 0.001) and the NR sign (P , 0.0001) were independent predictors for ACS, similar to our study; in the study by Otsuka et al., 14 LAP ,150 HU (P ¼ 0.007) threshold was set higher, but in our study with LAP ,30, ,60, and ,90 HU. Our study design is different from those that defined the NR sign as higher CT attenuation of the outer ring than the inner and no .130 HU 14,22 ; we set a higher threshold of ,200 HU for the outer rim, while keeping ,130 HU for the inner core. The outer rim may contain dense fibrosis mixed with mirco-calcification, inflammatory cells, or neo-angiogenesis 23 with contrast agent uptake, which may lead to higher HU than 130. Neo-angiogenesis was found more frequently in NR-sign plaque (48 vs. 30%) in an ex vivo study. 23 Contrary, in a comparative study with OCT, the NR sign was not associated with plaque inflammation, 10 despite being a strong prognostic marker for MACE in our population. We assume our distinct 'NR sign' criteria might be more sensitive for the detection of 'highrisk' lesions. We also observed a higher prevalence of NR-sign plaque in patients who suffered from MACE. A prospective mid-term outcome study 15 on a larger sample size defined 'high-risk plaque' based on LAP ,30 HU and an independent prediction of MACE during mid-term follow-up, while the NR sign was not included. 15 The criterion LAP ,30 HU is based on a culprit lesion analysis 9 in patients with ACS that had already occurred; thus, thrombotic appositions superimposed on ruptured lesions during ACS, which are characterized by lower CT densities, may explain why the LAP ,60 HU cut-off performed slightly better in our prospective study.
We observed an increasing cumulative number of plaques with increasing CT density, indicating more stable fibrous plaque in patients who remained MACE free. On the other hand, the relative percentage of LAP frequency in MACE-free patients was low, indicating a high probability of ruling out MACE in the absence of LAP.
Similarly, in our cohort, a low prevalence of the HRP criterion LAP ,30 HU in those who remained MACE free was noted, and low prevalence of the NR sign (2.8%) was also noted, similar to others. 15 The RI was higher in MACE but not significant predictive, possibly due to the inclusion of calcified nodules in mixed plaques into RI measurements, which artificially appear larger on CTA due to blooming artefacts, while other studies measured the RI in LAP only and found significance.
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The HRP criterion 'SC' was a weak-to-moderate predictor for ACS, while the cumulative number of patients who remained event free was high, limiting its sensitivity to depict 'high-risk' patients.
Second, we found a higher risk of MACE along with increasing non-calcifying plaque component. We describe a distinct novel plaque type score (0-4) for clinical practice for the estimation of total non-calcified vs. calcified plaque burden per coronary-AHAsegment. Our findings are in line with the PROSPECT trial, 26 which reported a very low rate of non-fibroatheroma (0.7%) in culprit lesions causing ACS. Third, our study proofs the excellent prognosis over a long-term period of 7.8 years, with zero MACE in patients with negative CTA, which is in line with previous short-and mid-term outcome trials. 4 -7 Further, MACE risk increased along with increasing stenosis severity in our cohort, similar to other trials, 4 ,5 based on the high accuracy of stenosis quantification by CTA. 27 In clinical practice, intensification of preventive actions is recommended in patients with HRP criteria. Statins 28 -30 have proven beneficial effects in reducing mortality even in patients with nonobstructive CAD on CTA, 28 related to a stabilizing effect on lipid-rich fibroatheromas by increasing the dense fibro-calcified plaque component, 29 e.g. due to the activation of anti-inflammatory pathways or extracellular matrix stimulation. 31 Due to the long-term follow-up design of our study, lesions may have undergone plaque component tissue changes from CTA until ACS occurred, as a result of the multifactorial atherogenesis pathways, influenced by life-style modifications or medication (e.g. statins). These dynamic changes over time may explain why HRP features were also found in patients who remained MACE free.
Study limitations † We excluded plaques with image quality limitations from quantitative HRP analysis. While total exclusion rate was low with 7.5%, the majority (90%) occurred in 64-slice CT exams, but not 128-slice dual-source CT. Iterative CT image reconstruction improves image quality and non-calcifying plaque delineation. NR sign illustrating (P , 0.001) higher MACE rate if present (P , 0.0001) (100% censored cases). † Due to patient selection, the majority had low-to-moderate CCS and only few patients had high CCS .400 AU. 33 
Conclusion
Outcome of patients with negative CTA is excellent over a longterm F/U period, while prognosis worsens with increasing stenosis severity and non-calcified plaque burden. The HRP features LAP ≤60 HU and the NR sign are the most powerful HRP criteria among all parameters for prediction of MACE, suggesting their integration into coronary risk stratification, as well as an intensification of individual preventive measures.
Supplementary data
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